A SINGLE CENTRE, CLINICAL STUDY IN 33 HEALTHY SUBJECTS TO EVALUATE THE SAFETY AND EFFICACY OF A TOWEL PRODUCT VIA TEWL INSTRUMENT, CLINICAL SKIN GRADING, SELF-ASSESSMENT, AND SELF-PERCEPTION QUESTIONNAIRE.

Prepared for:

Clean Skin Club
1240 Tangelo Terrace Unit B12
Delray Beach
FL 33444
USA

Prepared by:

PCR Corp
8 Richmond Road
Dukes Park
Chelmsford
Essex
CM2 6UA
United Kingdom

Draft Report v1: 26th October 2023
Final Report:

A SINGLE CENTRE, CLINICAL STUDY IN 33 HEALTHY SUBJECTS TO EVALUATE THE SAFETY AND EFFICACY OF A TOWEL PRODUCT VIA TEWL INSTRUMENT, CLINICAL SKIN GRADING, SELF-ASSESSMENT, AND SELF-PERCEPTION QUESTIONNAIRE.

PCR CORP REPORT NO: CSCCLI2M

I declare that the following report constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by PCR Corp were performed, where relevant, in accordance with the principles of Good Clinical Research Practice.

Barrie Drewitt ……
(Principal Investigator)

Date……..

Sophie Ellis ……..
(Project Manager)

Date……

QUALITY ASSURANCE STATEMENT:

This report has been audited and is considered to be an accurate description of the methods used and an accurate presentation of the data obtained during the conduct of the study.

Rob Sherrington ……..
(Quality Assurance)

Date……

TABLE OF CONTENTS

1. SUMMARY **4**
2. KEY STUDY PERSONNEL AND RESPONSIBILITIES **6**
3. INTRODUCTION AND OBJECTIVES **7**
4. STUDY DESIGN **7**
5. SELECTION OF SUBJECTS **7**
5.1 SCREENING 7
5.2 INCLUSION CRITERIA 8
5.3 EXCLUSION CRITERIA 9
5.4 PROHIBITIONS AND RESTRICTIONS 10
6. METHOD **10**
6.1 TEST ARTICLE 10
6.2 STUDY PROCEDURE 11
6.3 ASSESSMENTS 12
7. STUDY ETHICS **14**
7.1 DECLARATION OF HELSINKI 14
7.2 SUBJECT CONSENT 14
7.3 INDEMNITY PROVISION 14
8. QUALITY ASSURANCE **14**
9. RETENTION OF DATA **15**
10. REFERENCES **15**
11. RESULTS **16**
11.1 LOCATION AND DATES OF THE STUDY 16
11.2 SUBJECTS 16
11.3 ADVERSE EVENTS, ADVERSE REACTIONS AND SUBJECTS NOT COMPLETING THE STUDY 16
11.4 ASSESSMENTS AND STATISTICAL ANALYSIS 16
12. CONCLUSIONS **20**
13. APPENDIX 1: INFORMED CONSENT **22**
14. APPENDIX 2: PRE-TREATMENT QUESTIONNAIRE **26**
15. APPENDIX 3: INGREDIENTS LIST **28**
16. APPENDIX 4: SKIN EVALUATION GRADING SCALE **29**
17. APPENDIX 5: SUBJECT INFORMATION SHEET **30**
18. APPENDIX 6: SELF-PERCEPTION QUESTIONNAIRE **31**
19. APPENDIX 7: INDIVIDUAL TEWL DATA **32**
20. APPENDIX 8: INDIVIDUAL VISUAL GRADING – REDNESS OF ACNE LESIONS **33**
21. APPENDIX 9: INDIVIDUAL VISUAL GRADING – ERYTHEMA, EDEMA, DRYNESS, OTHER SKIN REACTIONS **34**
22. APPENDIX 10: INDIVIDUAL VISUAL GRADING – IGA **35**
23. APPENDIX 11: INDIVIDUAL VISUAL GRADING – FACIAL LESION COUNT **36**
24. APPENDIX 12: INDIVIDUAL TOLERABILITY SELF-ASSESSMENT RESPONSES **38**
25. APPENDIX 13: INDIVIDUAL SELF-PERCEPTION RESPONSES **39**

1. SUMMARY

Title:	A single centre, clinical study in 33 healthy subjects to evaluate the safety and efficacy of a Towel product via TEWL instrument, Clinical skin grading, Self-assessment, and Self-perception questionnaire.
Study design:	Single centre, home use clinical study.
Test Article:	1. Clean Skin Club Clean Towels XL
Duration of study:	6 weeks
Number of subjects:	33
Type of subjects:	Healthy male and female subjects aged 18+ years old. All ethnicities and skin types included. Subjects had mild to moderate outbreaks on the face at enrolment (IGA score of 2-3) and were normal facial towel users.
Method:	Potential subjects attended the testing facility for screening, Informed Consent was obtained and eligibility to participate was assessed via the inclusion/exclusion criteria. Accepted subjects then had the following assessments taken: - Tewameter® assessments of Trans-epidermal water loss (TEWL) taken from the face at baseline prior to test article use and after 6 weeks of home use. - Expert clinical skin grading for redness, dryness/scaling and facial swelling, IGA scoring and facial lesion counts for inflammatory (papules, pustules, and nodules) and non-inflammatory (open and closed comedones) at baseline prior to test article use and after 6 weeks of home use. - Tolerability self-assessment for safety (burning, stinging, itching or dryness/tightness) at baseline prior to test article use and week 6. - Self-Perception Questionnaire at baseline prior to test article use, week 3 and week 6.
Study Started:	w/c 21st August 2023
Study Ended:	w/c 2nd October 2023

Location:

PCR Corp
164A Plymouth Grove
Ardwick
Manchester
M13 0AF
United Kingdom

2. KEY STUDY PERSONNEL AND RESPONSIBILITIES

KEY PERSONNEL	GENERAL RESPONSIBILITIES
Principal Investigator (PI) Barrie Drewitt PCR Corp 8 Richmond Road Dukes Park Chelmsford Essex CM2 6UA United Kingdom Tel: 01245 934050	The Principal Investigator (PI) was responsible for ensuring sufficient resources were available to conduct the study and was responsible for the study design, review of the study protocol and report and ensuring that they concurred with the study design and findings reported.
Study Supervisor (SS) Andrew King PCR Corp 164A Plymouth Grove Ardwick Manchester M13 0AF United Kingdom Tel: 0161 791 1797	The Project Supervisor (PS) was responsible for the conduct of the study on a daily basis.
Project Manager (PM) Sophie Ellis PCR Corp 8 Richmond Road Dukes Park Chelmsford Essex CM2 6UA United Kingdom Tel: 01245 934050	The Project Manager (PM) was involved with the study design, compilation of study results, and writing the study protocol and report.
Project Coordinator (PC) Aviran Mulain Clean Skin Club 1240 Tangelo Terrace Unit B12 Delray Beach FL 33444 USA Email: aviran@cleanskinclub.com	The Project Coordinator (PC) was the primary point of contact on behalf of the Sponsor of this study and represented the Sponsor of this study.

3. INTRODUCTION AND OBJECTIVES

The objective of this study was to evaluate the safety and efficacy of a Towel product in 33 healthy male and female subjects via TEWL instrument, Clinical skin grading, Self-assessment, and Self-perception questionnaires over 6 weeks of home use.

To make the following claims:

- Clinically Tested/Proven
- Skin appeared clearer by X%
- Reduces Redness

Please note that it is the responsibility of the sponsor to determine the testing and study designs required for submission to entities such as the Home Shopping Network, QVC, etc.

4. STUDY DESIGN

Timepoint	Day 0	Week 3	Week 6
Visit	1		2
Inclusion/Exclusion	√		
TEWL	√		√
Expert clinical skin grading	√		√
Tolerability self-assessment for safety	√		√
Self-perception questionnaire	√	√	√
Product Distribution	√		
Adverse events check			√

Single centre, home use clinical study.

5. SELECTION OF SUBJECTS

5.1 SCREENING

An adequate number of subjects were enrolled so that a minimum of 30 subjects would be expected to complete the study. Subjects satisfied the following inclusion and exclusion criteria, were prepared to accept the prohibitions and restrictions, and gave written informed consent (Appendix 1).

The suitability of each subject to participate was confirmed prior to their acceptance onto the study by completion and review of a study specific pre-treatment questionnaire (Appendix 2).

5.2 INCLUSION CRITERIA

a. Healthy male or female subject aged 18+ years old.
b. All ethnicities and skin types to be included.
c. Subject must have mild to moderate outbreaks on the face at enrolment (IGA score of 2-3).
d. Subject must be normal facial towel users.
e. Willing to complete and sign a written Informed Consent.
f. Subject is willing to attend all study visits with a clean face, free of makeup and follow the study instructions and prohibitions.

5.3 EXCLUSION CRITERIA

a. Subject is pregnant, planning to become pregnant during the course of the study or nursing.
b. Subject is currently using concurrent medication likely to affect the response to the test article or confuse the results of the study.
c. Subject has a current skin disease, suffers with any type of skin condition or is under the treatment of a doctor for any facial skin condition (e.g. rosacea, eczema, psoriasis, seborrheic dermatitis, vitiligo, severe acne IGA score of 4).
d. Subject has cuts, scratches, abrasions, scarring, sun burn, birth marks, excessive hair, piercings, or tattoos, etc. in the facial area that would indicate a condition that would interfere with assessment or the safety of the subject.
e. Subject is currently or within the last month used any topical medications, OTC, or prescription retinoid, acne medication (e.g., benzoyl peroxide), hydroquinone, hydrocortisone, or salicylic acid products.
f. Subject has used Isotretinoin/Accutane, Retin-A, Retinol, in the last three months.
g. Known allergies or hypersensitivity to facial mists, facial serums, face masks, cleansers, moisturizers, sunscreen products, cosmetics, similar materials, or their ingredients.
h. Subject has recently used within the last 14 days a chemical peel or is currently using an in-home or professional chemical peel on their facial skin.
i. Subject has a compromised skin barrier due to sunburn, wounds, dermatological or cosmetic procedures, hair removal, laser treatment, etc.
j. Subject has had a cosmetic medical procedure in the test area such as injectable anti-wrinkle products, facial cosmetic surgery, etc. in the last year.
k. A fever in the last 12 hours, prior to start of the study.
l. Significant past medical history of hepatic, cancerous, multiple sclerosis, high blood pressure, renal, Thrombosis/Phlebitis, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease, which in the opinion of the Investigator would compromise the safety of the subject.
m. Insulin-dependent diabetes.
n. Subject is not currently participating in another study at PCR or other clinical testing facility.
o. Principal Investigator deems the subject an unsuitable candidate for this study.

5.4 PROHIBITIONS AND RESTRICTIONS

a. Subject must attend all study visits with a clean face, free of makeup and follow the study instructions and prohibitions.
b. Subject must refrain from using all facial treatments during the study including toxins, fillers, microdermabrasion, peels, facials, laser treatments, IPL, tightening treatments. Waxing and threading are allowed but not within two weeks of a study visit. Facial laser hair removal is not permitted.
c. Subject must refrain from using any new topical skin care products, cleansers, laundry detergents, fragrances and to continue with their normal skin care routine while participating in this study.
d. Subject must avoid excessive sun exposure and the use of sunbeds for the duration of the study.

6. METHOD

6.1 TEST ARTICLE

The test article was supplied by the Sponsor:

1. Clean Skin Club Clean Towels XL

The test article was used as supplied by the Sponsor according to the usage instructions provided by Sponsor: **Twice a day. Once in the morning and once in the evening.**

After washing, grab a Clean Towel. Gently pat the Clean Towel over the face, starting from the forehead and moving down to your chin. To do this, press the Clean Towel against the skin and lift, allowing the water to be absorbed with little to no friction. The skin around the eyes is particularly delicate. When drying this area, take care to gently pat without pulling or stretching the skin.

The Sponsor provided the ingredient listing (Appendix 3) and certified that the product supplied to PCR Corp for the clinical trial had been manufactured/formulated with ingredients that are safe and suitable for the product's stated purpose.

It was the responsibility of the Sponsor to determine, for each batch of test article, the identity, strength, purity, composition, and other characteristics which appropriately defined the test article before its use in the study. The determination of its stability and documentation of methods of synthesis and derivation were also the Sponsor's responsibility.

It was the responsibility of the Sponsor that the test article met all necessary transport regulations, particularly those regulations involving the carriage of hazardous goods and the import/export of goods, and that any costs including tax/duty were fully met by the Sponsor prior to receipt of the test article at PCR Corp. No liability with regard to safe receipt or costs involved in carriage of goods to any PCR Corp site were accepted.

On study completion, any remaining unused test articles will be disposed of, unless otherwise requested by the Sponsor, after issuance of the final report or 28 days after study completion, whichever comes first. Sponsors requesting the return of products will be liable for any costs incurred.

6.2 STUDY PROCEDURE

Baseline (Day 0) Study Visit 1: Potential subjects attended the testing facility for the screening visit at which time Informed Consent was obtained and eligibility of subjects was assessed and verified using the inclusion/exclusion criteria. Accepted subjects then sat resting for a period of at least 30 minutes in a controlled environment at a temperature of 22°C ± 2°C and at a relative humidity of 45% ± 5%.

Following the rest period, subjects underwent expert clinical skin grading assessments for baseline redness, dryness/scaling and facial swelling, IGA scoring and facial lesion counts. A baseline TEWL reading was also taken from the face. Subjects completed a baseline Tolerability self-assessment for safety (burning, stinging, itching or dryness/tightness) and a self-perception questionnaire.

The test article was then issued to the subject to use at home for the next 6 weeks and subjects received an information sheet with the directions for usage included.

Week 3: Subjects completed an online self-perception questionnaire.

Week 6 Study Visit 2: Subjects returned to the testing facility following 6 weeks of using the test article at home. Subjects were asked if there had been any changes to their health or medication since the previous visit. Subjects sat resting for a period of at least 30 minutes in a controlled environment at a temperature of 22°C ± 2°C and at a relative humidity of 45% ± 5%.

Following the rest period, subjects underwent repeated expert clinical skin grading assessments for redness, dryness/scaling and facial swelling, IGA scoring and facial lesion counts. A TEWL reading was also be taken from the face again.

Subjects completed a Tolerability self-assessment for safety (burning, stinging, itching or dryness/tightness) and a self-perception questionnaire to assess how they found using the product for the last 6 weeks. Subjects were then compensated for their time (end of study).

6.3 ASSESSMENTS

Tewameter® Probe assessments of Trans epidermal water loss (TEWL)

Evaporation of water from the skin occurs normally as part of the skin metabolism. However, when barrier function of the skin becomes even slightly damaged, water loss will increase (even though it may be invisible to the human eye). Trans-epidermal water loss was measured with the Tewameter® TM300 Probe (Courage and Khazaka; Koln, Germany. This method is an extremely effective method to measure barrier function of the skin. The measurement of the water evaporation and therefore TEWL, is based on the diffusion principle in an open chamber and is measured as g/m2/h. The density gradient is measured indirectly by two pairs of sensors in the probe attachment, one for temperature and the other for relative humidity. This density gradient is then analysed by a microprocessor in the instrument. A 15-minute warm-up period was allowed before using the Tewameter®. Measurements were taken from the cheek at baseline and week 6.

Expert Clinical Grading

The subject's skin was evaluated under standard lighting conditions by the same assessor using the below grading scales at each assessment timepoint: baseline and week 6.

PCR Clinical Grading Scale											
Descriptors	Type of Grading	0	1	2	3	4	5	6	7	8	9
Redness of acne lesions	Visual	No redness	Mild redness			Moderate redness			Severe redness		

Erythema, Edema and Dryness grading scale:

See Appendix 4 for detailed descriptions of the below scoring scale breakdown.

Reaction/Severity	None 0	Very Mild 1	Mild 2	Moderate 3	Severe 4
Erythema					
Edema					
Dryness					
Other skin reactions Specify: _____					

IGA Scoring Scale:

Score	Grade	Definition
0	Clear	Clear skin with no inflammatory or noninflammatory lesions
1	Almost Clear	Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion (one papules/pustule;)
2	Mild	Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
3	Moderate	Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
4	Severe	Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions

Facial Lesion Count:
Inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) were counted (separately) using the following diagram for reference of the four quadrants. The expert grader counted the amount and types of lesions for each separate quadrant.



Tolerability Self-Assessment
Subjects were asked to rate the severity of the following attributes: burning, stinging, itching and dryness/tightness of their facial skin at baseline and week 6 using the below scale:

Stinging	Burning	Itching	Dryness/tightness
0 = None	0 = None	0 = None	0 = None
1 = Mild	1 = Mild	1 = Mild	1 = Mild
2 = Moderate	2 = Moderate	2 = Moderate	2 = Moderate
3 = Severe	3 = Severe	3 = Severe	3 = Severe

Self-Perception Questionnaire (SPQ)
Subjects completed a self-perception questionnaire (SPQ) at baseline and following 3 weeks and 6 weeks of home use.

7. STUDY ETHICS

7.1 DECLARATION OF HELSINKI

The study conformed to the requirements of the 1964 Declaration of Helsinki and its subsequent amendments (World Medical Association; 2013)[1].

7.2 SUBJECT CONSENT

Subjects were informed of the nature, purpose and known risk of the study both orally and in writing and gave their written informed consent before participating in the study (Appendices 1 and 2). Subjects were advised that they were free to withdraw from the study at any time without being obliged to give a reason. They were compensated for their time and inconvenience.

7.3 INDEMNITY PROVISION

The Sponsor shall be responsible, without regard to legal liability, and shall indemnify PCR Corp, or any of their respective officers or employees in the event of claims for compensation from subjects suffering injury arising out of the administration or use of the test article, or of any procedure required under this protocol as a result of a subject participating in this study, except and insofar as such claims arise as a result of any negligent act or omission on the part of PCR Corp employees or any persons undertaking or involved in the study by arrangement with PCR Corp.

8. QUALITY ASSURANCE

The study was carried out within the spirit of the ICH Guidelines on Good Clinical Practice (ICH E6_R2) and other recognised guidelines[2]. An audit of the final report will be completed, for accuracy and completeness of presentation. Additionally, the study may be subject to the following Quality Assurance procedures:

- Review of protocol and protocol amendments for completeness, clarity, and adequacy.
- Inspection and/or audit of critical phases of study conduct for compliance with protocol and PCR Corp procedures.

PCR Corp Quality Assurance will inform PCR Corp management of any findings that may affect the integrity of the study.

9. RETENTION OF DATA

All raw data generated by PCR Corp during the course of the study, and including protocol and final report, will be retained in the PCR Corp archive for a minimum period of fifteen years from study completion. In the event of original data being transferred to the Sponsor at their request, exact copies will be so retained. At no time will archived data be destroyed without prior written approval of the Sponsor. All study data will be available at any time, by appointment, for inspection by the Sponsor or their authorised representative.

10. REFERENCES

1. World Medical Association (2013). "Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects". JAMA 310 (20): 2191–2194. doi:10.1001/jama.2013.281053.

2. ICH E6_R2, INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE, Current Step 4 version dated 9 November 2016.

11. RESULTS

11.1 LOCATION AND DATES OF THE STUDY

The study was performed at PCR Corp in Manchester, UK between w/c 21st August 2023 and completed w/c 2nd October 2023.

11.2 SUBJECTS

33 subjects were recruited into the study and all subjects completed the study.

11.3 ADVERSE EVENTS, ADVERSE REACTIONS AND SUBJECTS NOT COMPLETING THE STUDY

No adverse reactions were reported, and all 33 subjects completed the study.

11.4 ASSESSMENTS AND STATISTICAL ANALYSIS

Visual: 1) Descriptive Statistics (mean and standard deviation)
2) Change from Baseline (Signed-Rank-Test, percent of subjects improving)

Instruments: 1) Descriptive Statistics (mean and standard deviation)
2) Change from Baseline (T-Test, percent of subjects improving)

All statistical tests of hypothesis employed a level of significance of 0.05 and no adjustments were made for the number of tests performed.

[1] Percent change is calculated from the mean changes from baseline
[2] Percent change is calculated individually by subject and averaged (Note if 0 at baseline, % not calculated for that subject).

TEWL (Trans-epidermal water loss)

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	13.25	0.79	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	13.01	0.79	-1.83 %	-1.83 %	-0.24	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – redness of acne lesions

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	2.12	0.48	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.09	0.29	-95.71 %	-96.97 %	-2.03	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – Erythema

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	2.12	0.48	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.39	0.54	-81.43 %	-83.84 %	-1.73	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – Edema

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	0.00	0.00	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.00	0.00	N/A	N/A	0.00	0.0	0.00 %	1.00

* Significant change from baseline.

Visual grading – Dryness

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	1.52	0.51	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.55	0.46	-64.00 %	-69.70 %	-0.97	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – Other skin reactions

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	0.00	0.00	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.00	0.00	N/A	N/A	N/A	N/A	N/A	N/A

* Significant change from baseline.

Visual grading – IGA scoring

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	2.39	0.50	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.92	0.42	-61.39 %	-62.12 %	-1.47	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – Facial Lesion Count (Inflammatory lesions – papules/pustules/nodules)

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	10.27	3.13	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	2.61	2.40	-74.63 %	-76.80 %	-7.67	33.0	100.00 %	<0.01*

* Significant change from baseline.





Visual grading – Facial Lesion Count (Non-inflammatory lesions – open/closed comedones)

Timepoints	N	Mean	Standard Deviation	Percent Change [1]	Percent Change [2]	Mean Difference vs Baseline	N of Subjects Improved	% of Subjects Improved	Within Treatment Analysis (p-value)
Baseline	33	2.58	2.50	N/A	N/A	N/A	N/A	N/A	N/A
Week 6	33	0.79	1.02	-69.41 %	-75.36 %	-1.79	25.0	75.76 %	<0.01*

* Significant change from baseline.





Tolerability self-assessment

Feature	Timepoint	Responses			
		0	1	2	3
Stinging	Baseline	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
	Week 6	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Burning	Baseline	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
	Week 6	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Itching	Baseline	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
	Week 6	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
Dryness - Tightness	Baseline	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)
	Week 6	33 (100%)	0 (0.00%)	0 (0.00%)	0 (0.00%)

12. CONCLUSIONS

Under the conditions of the study the test article performed statistically significantly at reducing trans-epidermal water loss as measured by Tewameter values ($p<0.05$). A within-treatment analysis showed data from week 6 was significantly reduced when compared to baseline readings ($p<0.05$). Mean percent changes can be found under section 11.4.

Under the conditions of the study the test article performed statistically significantly at improving the appearance redness of acne lesions as measured by visual grading ($p<0.05$). A within-treatment analysis showed data from week 6 was significantly reduced when compared to baseline readings ($p<0.05$). Mean percent changes can be found under section 11.4.

Under the conditions of the study the test article performed statistically significantly at the reducing Erythema (redness) and Dryness as measured by visual grading ($p<0.05$). A within-treatment analysis showed data from week 6 was significantly reduced when compared to baseline readings ($p<0.05$). Mean percent changes can be found under section 11.4.

Under the conditions of the study the test article didn't cause Edema or other skin reactions as measured by visual grading. A within-treatment analysis showed data from week 6 was no different when compared to baseline readings ($p>0.05$) and all scores were 0.00.

Under the conditions of the study the test article performed statistically significantly at improving the overall appearance of skin inflammatory and non-inflammatory lesions as measured by IGA visual grading ($p<0.05$). A within-treatment analysis showed data from week 6 was significantly reduced when compared to baseline readings ($p<0.05$). Mean percent changes can be found under section 11.4.

Under the conditions of the study the test article performed statistically significantly at reducing the number of inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) as measured by visual facial lesion counts ($p<0.05$). A within-treatment analysis showed data from week 6 was significantly reduced when compared to baseline readings ($p<0.05$). Mean percent changes can be found under section 11.4.

Under the conditions of the study the test article didn't cause Stinging, Burning, Itching or dryness – tightness as measured by tolerability self-assessment questionnaires. The responses from week 6 were no different when compared to baseline and 100% of subjects answered with the response 0=None.

Summary of responses from the self-perception questionnaires:

WEEK 3

- 87.88% of subjects reported an improvement in the severity or frequency of breakouts following 3 weeks of use.
- 69.70% of subjects reported an improvement or a reduction in skin dryness following 3 weeks of use.
- 90.91% of subjects reported a reduction in skin oiliness following 3 weeks of use.
- 84.85% of subjects reported an improvement or a reduction in skin redness following 3 weeks of use.
- 72.73% of subjects reported an improvement or a reduction in skin sensitivity following 3 weeks of use.
- 96.97% of subjects reported an improvement in skin overall health following 3 weeks of use.

WEEK 6

- 96.97% of subjects reported an improvement in the severity or frequency of breakouts following 6 weeks of use.
- 78.79% of subjects reported an improvement or a reduction in skin dryness following 6 weeks of use.
- 93.94% of subjects reported a reduction in skin oiliness following 6 weeks of use.
- 100% of subjects reported an improvement in skin overall health following 6 weeks of use.
- 87.88% of subjects reported an improvement or a reduction in skin redness following 6 weeks of use.
- 78.79% of subjects reported an improvement or a reduction in skin sensitivity following 6 weeks of use.
- 100% of subjects reported they would continue using based on their experience following 6 weeks of use.
- 96.97% of subjects reported they found Clean Towels XL to be an effective tool in managing the frequency and severity of their acne following 6 weeks of use.
- 100% of subjects reported they would recommend to a friend or family member following 6 weeks of use.
- 84.85% of subjects reported they noticed improvements in their self-confidence or well-being as a results of the changes in their skin condition following 6 weeks of use.

13. APPENDIX 1: INFORMED CONSENT

Study Code: CSCCLI2M Subject No.:_____

INTRODUCTION

You are being asked to participate in a research study. Prior to giving your consent to be a subject, it is important that you take the time to read and understand what your participation would involve. This consent form may contain technical language which you may not understand. If you do not understand any of the information contained in this consent form, please ask the clinical staff and they will help answer any questions you may have.

You will be provided with a signed copy of this consent form and any other necessary written information before the start of the study.

OBJECTIVE

The objective of this research is to evaluate the safety and efficacy of one product in 30 healthy male and female subjects over 6-weeks of home use. One test article will be used during the 6-week study, and you will need to attend the testing facility for 2 visits.

TEST PRODUCT

One test article will be used in this study and usage instructions will be provided to you.

STUDY PROCEDURES

Baseline (Day 0) Study Visit 1 – Potential subjects will attend the testing facility for the screening visit at which time Informed Consent will be obtained and eligibility of subjects will be assessed and verified using the inclusion/exclusion criteria. Accepted subjects will then sit resting for a period of at least 30 minutes in a controlled environment at a temperature of 22°C ± 2°C and at a relative humidity of 45% ± 5%.

Following the rest period, subjects will undergo expert clinical skin grading assessments for baseline redness, dryness/scaling and facial swelling, IGA scoring and facial lesion counts. A baseline TEWL reading will also be taken from the face. Subjects will complete a baseline Tolerability self-assessment for safety (burning, stinging, itching or dryness/tightness) and a self-perception questionnaire.

The test article will then be issued to the subject to use at home for the next 6 weeks and subjects will receive an information sheet with the directions for usage included.

Week 3: Online self-perception questionnaire.

Week 6 Visit 2: Subjects will return to the testing facility following 6 weeks using the test article at home. Subjects will be asked if there have been any changes to their health or medication since the previous visit. Subjects will sit resting for a period of at least 30 minutes in a controlled environment at a temperature of 22°C ± 2°C and at a relative humidity of 45% ± 5%.

Following the rest period, subjects will undergo repeated expert clinical skin grading assessments for redness, dryness/scaling and facial swelling, IGA scoring and facial lesion counts. A TEWL reading will also be taken from the face.

Subjects will complete a Tolerability self-assessment for safety (burning, stinging, itching or dryness/tightness) and a self-perception questionnaire to assess how they found using the product for the last 6 weeks. Subjects will be compensated for their time (end of study).

RISKS

To the best of our knowledge, these products are not expected to induce an allergic reaction. While the potential for irritation or other reactions during this study are minimal, it is possible for a reaction to occur. Expected reactions for these test article categories are mild in nature and may include the following: redness, stinging, itching, or peeling. In addition to the risks described, there may be other risks that are currently unforeseeable. No significant adverse reactions are expected to occur. However, if you develop an adverse reaction or complication as a result of your participation in this study, medical treatment will be provided by clinical staff nurses at PCR Corp, or you will be referred for appropriate treatment at no cost.

The provision of such medical care is not an admission of legal responsibility. You will be followed by PCR Corp until the adverse reaction has resolved. No additional compensation will be available to you. Neither the sponsoring company nor the investigating company will be held responsible for any future medical expenses.

BENEFITS

While it is likely that you will not receive any direct benefit from your participation in the study, the study results may have the potential to increase scientific knowledge about skincare products and may allow for new and improved products to be marketed.

NEW FINDINGS

You may experience risks or side effects that are not known at this time. If new information becomes available that might influence your willingness to stay in the study, we will let you know as soon as possible.

IN CASE OF STUDY RELATED INJURY

If you are injured while participating in this study, PCR Corp will provide you with treatment. If your illness or injury is the result of the study products or any procedure required by the study that you would not have undergone were it not for your participation in the study, the sponsor will pay usual and customary medical fees for reasonable and necessary treatment, provided you have not already otherwise been properly reimbursed by your insurance, a government program, or other third party coverage for such medical expenses. The sponsor is not responsible for expenses that are due to pre-existing medical conditions, underlying disease, procedures which would have been performed even if you were not participating in the study, your negligence or wilful misconduct, or the negligence or wilful misconduct of institution, principal investigators, or third parties. No funds have been set aside by the sponsor to compensate you for lost wages, disability, or discomfort due to your participation in this study. You do not give up any legal rights as a research participant by signing this consent form.

COMPENSATION FOR INJURY

No significant adverse reactions are expected to occur. However, if you develop an adverse reaction or complication as a result of your participation in this study, medical treatment will be provided by clinical study staff at PCR Corp, or you will be referred for appropriate treatment at no cost to you. Provisions of such medical care are not an admission of legal responsibility. You will be followed by PCR Corp until the adverse reaction has resolved. No additional compensation will be available to you. Neither the sponsoring company nor the investigating company will be held responsible for any future medical expenses. In no way does signing this consent form waive your legal rights nor does it relieve the investigators, Sponsor or involved institutions from their legal and professional responsibilities.

FEMALES OF CHILDBEARING POTENTIAL

Pregnant and/or nursing women may not take part in this study. Signing and dating this consent form means that you are stating that you are not pregnant, planning a pregnancy, or nursing at the start of the study.

The test products may involve unknown risks to you, your nursing infant, or your unborn child if you become pregnant while on the study. By signing this form, you agree to practice an acceptable method of birth control for the duration of the study.

CONFIDENTIALITY

Information concerning you that is obtained in connection with this study will be kept confidential by PCR Corp, except that the sponsoring company whose products are being tested will receive a copy of the study records. The data will be uniquely coded to protect your identity. In addition, the study investigator, third party regulatory authorities, including the U.S. Food and Drug Administration (FDA), IRB/IEC or the sponsor (including monitors and auditors), may inspect the records of the study. Therefore, total privacy cannot be guaranteed.

Your signature on the Informed Consent provides your permission for these agencies to view your personal information and the study data.

CONTACT INFORMATION

If you have any questions about this study or in the case of an emergency, contact: **Andrew King** on **0161 791 1797.**

MEDICAL TREATMENT

In the event of an emergency, dial 999. If you receive any medical care during the course of the study, inform medical personnel that you are participating in a research study. Please contact PCR Corp staff as soon as possible to inform them of your condition.

VOLUNTARY PARTICIPATION/WITHDRAWAL

Your participation in this research study is strictly voluntary. You may refuse to participate or may discontinue participation at any time during the study without penalty or loss of benefits to which you are otherwise entitled. However, you must contact the test facility and inform a clinical staff member of your decision to withdraw from the study. If you agree to participate in the study, you are also agreeing to provide PCR Corp with accurate information and to follow study instructions as given to you. If you fail to follow study instructions, you may be asked to discontinue participation.

Your participation in the study may be discontinued at any time without your consent by PCR Corp, regulatory agencies, or the sponsoring company for reasons of but not limited to a severe side effect and accompanying illness, or if you do not follow study instructions.

NON-DISCLOSURE

As a condition to your participation in the study you are asked not to discuss any information regarding the products that you are testing, your experiences with the products, or your opinion of the products with anyone outside of the testing facility. By your signature on the Consent, you are agreeing to abide by this condition of participation.

COMPENSATION

If you agree to participate in this study, you will be paid £XX upon completion of the study.

PHOTOGRAPHY AUTHORIZATION

As a required part of this study, photography maybe conducted. By signing your name at the end of this form, you give the study team, the sponsoring company, and their affiliates, the right to take, use, reproduce, and distribute photographs from this study. These photos will only be used to document reactions to the test article you may have. We will do everything possible to protect your identity. Your full name will not be used with the photographs.

CONSENT TO PARTICIPATE

I know that my participation in this study is voluntary and that I have the right to refuse to participate. I know that I may withdraw from the study at any time without penalty or loss of benefits to which otherwise entitled. If, at the discretion of the Investigator or the sponsor, it is best to discontinue my participation for reasons other than a failure to obey the directions of the study, you will be paid in full or for the portion of the study you have completed once the study is over.

CONSENT

I have read all of the pages of this consent form and have been given an opportunity to ask questions about this study. Answers to such questions (if any) were satisfactory. I am at least eighteen years old and without reservation give my consent to serve as a subject in this study. By signing this form, I have not given up any of my legal rights as a research subject. I will receive a copy of this signed and dated consent document.

You are making a decision whether or not to participate. Your signature indicates that you have decided to participate, having read the information provided above.

Subject's Name Printed: First	**Middle Initial**	**Last**
Subject's Signature		**Date**
Signature of Person Conducting Consent Discussion		**Date**
Subject Number		

14. APPENDIX 2: PRE-TREATMENT QUESTIONNAIRE

Study Code: CSCCLI2M Subject No.:_____

STRICTLY CONFIDENTIAL

Demographics		
Race (check one):	**Date of Birth:**	**Age:**
_____ White (Caucasian, White British, White Irish, White Gypsy/Traveler) _____ Black (African, African Descent, Afro-Caribbean) _____ Asian (Chinese, Japanese, Pakistani, Bangladeshi) _____ Indigenous (Inuit, Indian, Filipino, Alaskan Native, Native Hawaiian) _____ Bi Racial (any mixed race)	____/_____/_____	_____
	Skin type: _____	
	Gender (Circle one):	
	Male Female	

	Inclusion Criteria	**Yes**	**No**
1.	Healthy male or female subject aged 18+ years old.	☐	☐
2.	All ethnicities and skin types to be included.	☐	☐
3.	Subject must have mild to moderate outbreaks on the face at enrolment (IGA score of 2-3).	☐	☐
4.	Subject must be normal facial towel users.	☐	☐
5.	Willing to complete and sign a written Informed Consent.	☐	☐
6.	Subject is willing to attend all study visits with a clean face, free of makeup and follow the study instructions and prohibitions.	☐	☐
	Exclusion Criteria	**Yes**	**No**
1.	Subject is pregnant, planning to become pregnant during the course of the study or nursing.	☐	☐
2.	Subject is currently using concurrent medication likely to affect the response to the test article or confuse the results of the study.	☐	☐
3.	Subject has a current skin disease, suffers with any type of skin condition or is under the treatment of a doctor for any facial skin condition (e.g. rosacea, eczema, psoriasis, seborrheic dermatitis, vitiligo, severe acne IGA score of 4).	☐	☐
4.	Subject has cuts, scratches, abrasions, scarring, sun burn, birth marks, excessive hair, piercings, or tattoos, etc. in the facial area that would indicate a condition that would interfere with assessment or the safety of the subject.	☐	☐
5.	Subject is currently or within the last month used any topical medications, OTC, or prescription retinoid, acne medication (e.g., benzoyl peroxide), hydroquinone, hydrocortisone, or salicylic acid products.	☐	☐
6.	Subject has used Isotretinoin/Accutane, Retin-A, Retinol, in the last three months.	☐	☐
7.	Known allergies or hypersensitivity to facial mists, facial serums, face masks, cleansers, moisturizers, sunscreen products, cosmetics, similar materials, or their ingredients.	☐	☐

8.	Subject has recently used within the last 14 days a chemical peel or is currently using an in-home or professional chemical peel on their facial skin.	☐	☐
9.	Subject has a compromised skin barrier due to sunburn, wounds, dermatological or cosmetic procedures, hair removal, laser treatment, etc.	☐	☐
10.	Subject has had a cosmetic medical procedure in the test area such as injectable anti-wrinkle products, facial cosmetic surgery, etc. in the last year.	☐	☐
11.	A fever in the last 12 hours, prior to start of the study.	☐	☐
12.	Significant past medical history of hepatic, cancerous, multiple sclerosis, high blood pressure, renal, Thrombosis/Phlebitis, cardiac, pulmonary, digestive, haematological, neurological, locomotor or psychiatric disease, which in the opinion of the Investigator would compromise the safety of the subject.	☐	☐
13.	Insulin-dependent diabetes.	☐	☐
14.	Subject is not currently participating in another study at PCR or other clinical testing facility.	☐	☐
15.	Principal Investigator deems the subject an unsuitable candidate for this study.	☐	☐
Prohibitions/Requirements		**Yes**	**No**
1.	Subject must attend all study visits with a clean face, free of makeup and follow the study instructions and prohibitions.	☐	☐
2.	Subject must refrain from using all facial treatments during the study including toxins, fillers, microdermabrasion, peels, facials, laser treatments, IPL, tightening treatments. Waxing and threading are allowed but not within two weeks of a study visit. Facial laser hair removal is not permitted.	☐	☐
3.	Subject must refrain from using any new topical skin care products, cleansers, laundry detergents, fragrances and to continue with their normal skin care routine while participating in this study.	☐	☐
4.	Subject must avoid excessive sun exposure and the use of sunbeds for the duration of the study.	☐	☐

Have you ever had any problems related to the use of any of the following types of material?

Material	Yes	No	When? – Which products? – What happens?
Towelette/Viscose			
Other personal healthcare products			

Questionnaire checked and confirmed by:

Technician's initials & Date: _____

15. APPENDIX 3: INGREDIENTS LIST

TEST ARTICLE 1 - Clean Skin Club Clean Towels XL

100% viscose (dry) towelette

16. APPENDIX 4: SKIN EVALUATION GRADING SCALE

Description of Reactions and Severity Classification used for clinical skin evaluation

Reaction/ Severity	None (0)	Very Mild (1)	Mild (2)	Moderate (3)	Severe (4)
Erythema	No apparent cutaneous involvement	Negligible erythema	Faint, just perceptible macular erythema in a speckled/ follicular, patchy, or confluent pattern (pinking)	Well defined erythema in a confluent pattern (definite redness)	Severe Erythema – strong or brisk erythema reaction (Beet redness)
Edema	No edematous areas	Negligible	Faint edema, just perceptible raised area	Definite edema, raised area(s)	Severe edema, clearly raised area
Dryness	No dryness visible	Patchy, slight powderiness w/ small scales	General, slight powderiness with small lifting scales	General, moderate powderiness, with cracking and scales	General heavy powderiness with creaking and lifting scales
Other Skin Reaction					

17. APPENDIX 5: SUBJECT INFORMATION SHEET

Study Code: CSCCLI2M Subject No.: _____

You have agreed to participate in a research study. By agreeing to participate, you are also agreeing to the following prohibitions and restrictions:

- Subject must attend all study visits with a clean face, free of makeup and follow the study instructions and prohibitions.
- Subject must refrain from using all facial treatments during the study including toxins, fillers, microdermabrasion, peels, facials, laser treatments, IPL, tightening treatments. Waxing and threading are allowed but not within two weeks of a study visit. Facial laser hair removal is not permitted.
- Subject must refrain from using any new topical skin care products, cleansers, laundry detergents, fragrances and to continue with their normal skin care routine while participating in this study.
- Subject must avoid excessive sun exposure and the use of sunbeds for the duration of the study.

The study schedule is as follows:

Visit 1 (Study Day 0): **w/c 21st August 2023** – Duration approx. 1.5 hours
Week 3: **w/c 11th September 2023** – online SPQ only
Visit 2 (Week 6): **w/c 2nd October 2023** – Duration approx. 1 hour

You must come in for all visits; no misses will be allowed. If you are unable to come in for a visit, your participation will be discontinued.

Upon completion of this study w/c 2nd October 2023 you will receive £XX for your participation.

If you have any questions about this study or in the case of a suspected allergic reaction, call **Andrew King** on **0161 791 1797** during normal business hours.

USAGE INSTRUCTIONS:

Twice a day. Once in the morning and once in the evening.

After washing, grab a Clean Towel. Gently pat the Clean Towel over the face, starting from the forehead and moving down to your chin. To do this, press the Clean Towel against the skin and lift, allowing the water to be absorbed with little to no friction. The skin around the eyes is particularly delicate. When drying this area, take care to gently pat without pulling or stretching the skin.

Use only as directed (for external use only).
Please report any irritation to the study staff.

18. APPENDIX 6: SELF-PERCEPTION QUESTIONNAIRE

BASELINE:

1. How long have you been experiencing light to mild acne?
2. How often do you change or wash your regular fabric face towel?
3. Have you used any medication, creams, or treatments specifically for your acne?
4. Are you comfortable with documenting your experience during the trial?

WEEK 3:

1. Have you noticed an improvement in the severity or frequency of breakouts?
2. Have you noticed any changes in your skin's dryness after using Clean Towels XL?
3. Have you noticed any changes in your skin's oiliness after using Clean Towels XL?
4. Have you noticed any changes in your skin's redness after using Clean Towels XL?
5. Have you noticed any changes in your skin's sensitivity after using Clean Towels XL?
6. Have you noticed any changes in your skin's overall health after using Clean Towels XL?

WEEK 6:

1. Have you noticed an improvement in the severity or frequency of breakouts?
2. Have you noticed any changes in your skin's dryness after using Clean Towels XL?
3. Have you noticed any changes in your skin's oiliness after using Clean Towels XL?
4. Have you noticed any changes in your skin's overall health after using Clean Towels XL?
5. Have you noticed any changes in your skin's redness after using Clean Towels XL?
6. Have you noticed any changes in your skin's sensitivity after using Clean Towels XL?
7. Would you consider continuing to use Clean Towels XL, based on your experience?
8. Have you found Clean Towels XL to be an effective tool in managing the frequency and severity of your acne?
9. Would you recommend Clean Towels XL to a friend or family member?
10. After using Clean Towels XL, have you noticed improvements in your self-confidence or well-being as a result of changes in your skin condition?
11. While using Clean Towels XL, did you experience any unexpected benefits? Please describe.
12. Would you go back to using a regular fabric face towel after trying Clean Towels XL? Why or why not?

19. APPENDIX 7 – INDIVIDUAL TEWL DATA

SUB NO	SITE	BASELINE	WEEK 6
1	TREATED	13.62	13.21
2	TREATED	13.72	13.45
3	TREATED	12.42	12.20
4	TREATED	14.06	13.71
5	TREATED	12.22	11.95
6	TREATED	12.86	12.65
7	TREATED	14.42	14.33
8	TREATED	13.09	12.70
9	TREATED	13.25	12.95
10	TREATED	14.01	13.80
11	TREATED	13.30	13.14
12	TREATED	12.46	12.17
13	TREATED	14.29	14.08
14	TREATED	13.31	13.19
15	TREATED	12.12	11.76
16	TREATED	12.45	12.10
17	TREATED	13.22	13.03
18	TREATED	12.03	11.79
19	TREATED	13.91	13.70
20	TREATED	13.73	13.41
21	TREATED	14.40	14.05
22	TREATED	14.01	13.86
23	TREATED	13.91	13.51
24	TREATED	12.07	12.00
25	TREATED	14.09	13.71
26	TREATED	12.68	12.44
27	TREATED	14.48	14.39
28	TREATED	12.14	11.97
29	TREATED	12.34	12.28
30	TREATED	12.56	12.26
31	TREATED	12.87	12.78
32	TREATED	13.30	12.95
33	TREATED	14.00	13.82
MEAN		13.25	13.01
STDEV		0.79	0.79

20. APPENDIX 8: INDIVIDUAL VISUAL GRADING – REDNESS OF ACNE LESIONS

SUB NO	SITE	BASELINE	Week 6
1	TREATED	2.0	0.0
2	TREATED	2.0	0.0
3	TREATED	2.0	0.0
4	TREATED	3.0	1.0
5	TREATED	2.0	0.0
6	TREATED	1.0	0.0
7	TREATED	2.0	0.0
8	TREATED	2.0	0.0
9	TREATED	2.0	0.0
10	TREATED	2.0	0.0
11	TREATED	3.0	0.0
12	TREATED	2.0	0.0
13	TREATED	2.0	0.0
14	TREATED	3.0	0.0
15	TREATED	2.0	0.0
16	TREATED	2.0	0.0
17	TREATED	2.0	0.0
18	TREATED	3.0	0.0
19	TREATED	2.0	0.0
20	TREATED	2.0	0.0
21	TREATED	1.0	0.0
22	TREATED	2.0	0.0
23	TREATED	3.0	1.0
24	TREATED	2.0	0.0
25	TREATED	2.0	0.0
26	TREATED	3.0	1.0
27	TREATED	2.0	0.0
28	TREATED	2.0	0.0
29	TREATED	2.0	0.0
30	TREATED	2.0	0.0
31	TREATED	2.0	0.0
32	TREATED	2.0	0.0
33	TREATED	2.0	0.0
MEAN		2.12	0.09
STDEV		0.48	0.29

21. APPENDIX 9: INDIVIDUAL VISUAL GRADING – ERYTHEMA, EDEMA, DRYNESS, OTHER SKIN REACTIONS

SUB NO	SITE	BASELINE				WEEK 6			
		Erythema	Edema	Dryness	Other	Erythema	Edema	Dryness	Other
		Grade	Grade	Grade	Grade	Grade	Grade	Grade	Grade
1	TREATED	2.0	0	1.0	0	1	0	0.5	0
2	TREATED	2.0	0	1.0	0	1	0	0.5	0
3	TREATED	2.0	0	1.0	0	1	0	0.5	0
4	TREATED	3.0	0	2.0	0	1.5	0	1	0
5	TREATED	2.0	0	1.0	0	1	0	0	0
6	TREATED	1.0	0	1.0	0	0	0	0.5	0
7	TREATED	2.0	0	1.0	0	0	0	0	0
8	TREATED	2.0	0	2.0	0	0	0	0.5	0
9	TREATED	2.0	0	1.0	0	0	0	0	0
10	TREATED	2.0	0	1.0	0	0	0	0	0
11	TREATED	3.0	0	1.0	0	1	0	0	0
12	TREATED	2.0	0	2.0	0	0	0	1	0
13	TREATED	2.0	0	2.0	0	0	0	1	0
14	TREATED	3.0	0	2.0	0	1	0	1	0
15	TREATED	2.0	0	2.0	0	0	0	1	0
16	TREATED	2.0	0	1.0	0	0	0	0	0
17	TREATED	2.0	0	1.0	0	0	0	0	0
18	TREATED	3.0	0	1.0	0	1	0	0	0
19	TREATED	2.0	0	1.0	0	0	0	0	0
20	TREATED	2.0	0	2.0	0	0	0	1	0
21	TREATED	1.0	0	2.0	0	0	0	1	0
22	TREATED	2.0	0	2.0	0	1	0	1	0
23	TREATED	3.0	0	2.0	0	1.5	0	1	0
24	TREATED	2.0	0	2.0	0	0	0	1	0
25	TREATED	2.0	0	2.0	0	0	0	1	0
26	TREATED	3.0	0	1.0	0	1	0	0	0
27	TREATED	2.0	0	1.0	0	1	0	0	0
28	TREATED	2.0	0	2.0	0	0	0	1	0
29	TREATED	2.0	0	2.0	0	0	0	1	0
30	TREATED	2.0	0	2.0	0	0	0	1	0
31	TREATED	2.0	0	1.0	0	0	0	0	0
32	TREATED	2.0	0	2.0	0	0	0	1	0
33	TREATED	2.0	0	2.0	0	0	0	0.5	0
MEAN		2.12	0.00	1.52	0.00	0.39	0.00	0.55	0.00
STDEV		0.48	0.00	0.51	0.00	0.54	0.00	0.46	0.00

22. APPENDIX 10: INDIVIDUAL VISUAL GRADING – IGA

SUB NO	SITE	BASELINE	Week 6
1	TREATED	2.0	0.5
2	TREATED	3.0	1.0
3	TREATED	3.0	1.5
4	TREATED	2.0	1.0
5	TREATED	2.0	0.5
6	TREATED	3.0	1.0
7	TREATED	2.0	0.5
8	TREATED	2.0	0.0
9	TREATED	3.0	1.5
10	TREATED	3.0	2.0
11	TREATED	2.0	1.0
12	TREATED	3.0	1.5
13	TREATED	2.0	1.0
14	TREATED	3.0	1.0
15	TREATED	2.0	1.0
16	TREATED	2.0	0.5
17	TREATED	2.0	0.5
18	TREATED	3.0	1.0
19	TREATED	2.0	1.0
20	TREATED	2.0	1.0
21	TREATED	2.0	0.5
22	TREATED	3.0	1.0
23	TREATED	2.0	0.5
24	TREATED	2.0	1.0
25	TREATED	2.0	0.5
26	TREATED	3.0	1.5
27	TREATED	2.0	1.0
28	TREATED	2.0	0.5
29	TREATED	3.0	1.0
30	TREATED	3.0	1.0
31	TREATED	2.0	0.5
32	TREATED	2.0	1.0
33	TREATED	3.0	1.5
MEAN		**2.39**	**0.92**
STDEV		**0.50**	**0.42**

23. APPENDIX 11: INDIVIDUAL VISUAL GRADING – FACIAL LESION COUNT

Inflammatory lesions

Subject Number	BASELINE												
	Quadrant 1			Quadrant 2			Quadrant 3			Quadrant 4			Total Lesions
	papules	pustules	nodules	papules	pustules	nodules	papules	pustules	nodules	papules	pustules	nodules	
1	2	2	0	0	1	0	3	1	1	1	1	1	13
2	0	3	0	1	0	0	2	1	0	1	1	0	9
3	0	3	0	1	0	0	2	2	0	1	1	0	10
4	0	2	0	1	0	0	2	1	0	3	2	0	11
5	0	3	0	1	1	0	2	2	0	1	1	0	11
6	0	3	0	1	1	0	2	3	0	2	3	0	15
7	2	1	0	0	0	0	5	1	0	3	2	0	14
8	1	2	0	0	0	0	3	3	0	2	2	0	13
9	2	2	0	0	0	0	3	2	0	1	1	0	11
10	0	2	0	0	0	0	2	0	0	1	0	0	5
11	0	2	0	0	0	0	1	1	0	1	1	0	6
12	2	1	0	0	0	0	2	1	0	2	2	0	10
13	0	3	0	0	0	0	2	3	0	3	3	0	14
14	1	2	0	0	0	0	1	1	0	1	0	0	6
15	0	3	0	0	0	0	1	1	0	0	1	0	6
16	0	2	0	0	0	0	2	1	0	1	0	0	6
17	1	2	0	0	0	0	2	1	0	1	0	0	7
18	1	2	0	1	0	0	1	1	0	1	1	0	8
19	1	2	0	2	0	0	3	1	0	3	2	0	14
20	2	3	0	1	0	0	2	2	0	2	2	0	14
21	0	2	0	1	0	0	1	1	0	1	0	0	6
22	0	2	1	1	0	0	2	3	0	3	2	0	14
23	0	3	0	1	0	0	2	1	0	1	1	0	9
24	1	2	0	1	0	0	2	2	0	2	3	0	13
25	0	3	0	1	0	0	2	0	0	1	0	0	7
26	1	2	0	1	1	0	3	1	0	1	2	0	12
27	1	2	0	2	0	0	4	2	0	3	0	0	14
28	0	3	0	1	0	0	1	1	0	2	0	0	8
29	0	2	0	2	0	0	1	1	0	2	2	0	10
30	0	3	0	1	0	0	3	2	0	2	2	0	13
31	2	1	0	1	0	0	1	1	0	1	0	0	7
32	1	2	0	2	1	0	2	1	0	2	2	0	13
33	1	3	1	1	0	0	1	1	0	2	0	0	10
Mean	0.67	2.27	0.06	0.76	0.15	0.00	2.06	1.39	0.03	1.64	1.21	0.03	10.27
Standard Deviation	0.78	0.63	0.24	0.66	0.36	0.00	0.93	0.79	0.17	0.82	0.99	0.17	3.13

Subject Number	WEEK 6												
	Quadrant 1			Quadrant 2			Quadrant 3			Quadrant 4			Total Lesions
	papules	pustules	nodules	papules	pustules	nodules	papules	pustules	nodules	papules	pustules	nodules	
1	0	0	0	0	0	0	1	0	0	0	0	0	1
2	0	1	0	0	0	0	0	0	0	1	1	0	3
3	0	1	0	0	0	0	1	1	0	0	0	0	3
4	0	0	0	1	0	0	0	0	0	1	1	0	3
5	0	1	0	0	0	0	1	0	0	0	0	0	2
6	0	1	0	1	0	0	1	1	0	1	1	0	6
7	0	0	0	0	0	0	2	1	0	1	1	0	5
8	0	0	0	0	0	0	1	1	0	1	1	0	4
9	1	0	0	0	0	0	1	0	0	0	0	0	2
10	0	0	0	0	0	0	1	0	0	0	0	0	1
11	0	0	0	0	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	2	1	0	1	1	0	5
13	0	1	0	0	1	0	1	1	0	1	1	0	6
14	0	0	0	0	0	0	0	0	0	0	0	0	0
15	1	0	0	0	0	0	0	0	0	1	0	0	2
16	0	0	0	0	0	0	1	1	0	0	0	0	2
17	0	1	0	1	0	0	1	1	0	0	0	0	4
18	0	0	0	1	0	0	0	0	0	0	0	0	1
19	1	0	0	0	0	0	1	1	0	1	0	0	4
20	2	3	0	0	0	0	2	1	0	1	1	0	10
21	0	0	0	0	0	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	1	0	0	0	0	0	1
23	0	0	0	0	0	0	0	0	0	0	0	0	0
24	1	0	0	0	0	0	2	1	0	1	0	0	5
25	0	0	0	0	0	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	1	0	0	0	0	0	1
27	0	0	0	1	0	0	2	2	0	1	0	0	6
28	0	0	0	0	0	0	0	0	0	1	0	0	1
29	0	0	0	0	0	0	0	0	0	1	0	0	1
30	0	0	0	0	0	0	1	0	0	0	0	0	1
31	0	0	0	0	0	0	0	0	0	0	0	0	0
32	1	1	0	0	0	0	1	0	0	1	1	0	5
33	0	0	0	0	0	0	0	0	0	1	0	0	1
Mean	0.21	0.30	0.00	0.15	0.03	0.00	0.76	0.39	0.00	0.48	0.27	0.00	2.61
Standard Deviation	0.48	0.64	0.00	0.36	0.17	0.00	0.71	0.56	0.00	0.51	0.45	0.00	2.40

Non-Inflammatory lesions

Subject Number	BASELINE								
	Quadrant 1		Quadrant 2		Quadrant 3		Quadrant 4		Total Lesions
	open comedones	closed comedones	open comedones	closed comedones	open comedones	closed comedones	open comedones	closed comedones	
1	0	1	2	0	0	0	0	0	3
2	0	0	1	0	0	0	0	0	1
3	0	0	0	0	0	0	2	0	2
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	2	0	0	2
7	0	1	0	0	0	0	0	2	3
8	2	0	1	0	0	0	0	0	3
9	2	1	0	0	0	0	0	0	3
10	1	0	2	0	0	0	0	0	3
11	0	0	0	0	0	0	2	2	4
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	1	0	0	0	0	0	0	0	1
15	0	0	0	0	0	2	0	0	2
16	3	0	0	0	0	0	0	0	3
17	0	0	0	1	1	2	1	1	6
18	2	1	0	2	0	0	0	0	5
19	1	0	1	0	0	0	0	0	2
20	0	1	0	0	0	0	0	0	1
21	0	1	1	0	0	0	2	2	6
22	0	0	1	0	0	2	0	0	3
23	1	0	1	0	0	0	0	0	2
24	0	0	0	0	0	0	1	0	1
25	0	0	0	0	0	3	0	2	5
26	0	1	0	1	0	0	0	0	2
27	0	0	0	0	0	0	0	0	0
28	0	0	0	1	2	2	2	1	8
29	0	0	0	0	0	0	1	0	1
30	0	0	0	0	0	0	0	0	0
31	0	1	2	0	3	1	1	3	11
32	0	1	1	0	0	0	0	0	2
33	0	0	0	0	0	0	0	0	0
Mean	0.39	0.27	0.39	0.15	0.18	0.42	0.36	0.39	2.58
Standard Deviation	0.79	0.45	0.66	0.44	0.64	0.87	0.70	0.83	2.50

Subject Number	WEEK 6								
	Quadrant 1		Quadrant 2		Quadrant 3		Quadrant 4		Total Lesions
	open comedones	closed comedones	open comedones	closed comedones	open comedones	closed comedones	open comedones	closed comedones	
1	0	0	1	0	0	0	0	0	1
2	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	1	0	1
4	0	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	1	1
8	1	0	0	0	0	0	0	0	1
9	0	0	0	0	0	0	0	0	0
10	0	0	1	0	0	0	0	0	1
11	0	0	0	0	0	1	1	1	3
12	0	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	2	0	0	2
16	1	0	0	0	0	0	0	0	1
17	0	0	0	0	0	2	1	0	3
18	1	0	0	1	0	0	0	0	2
19	0	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	1	1	2
22	0	0	0	0	0	1	0	0	1
23	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
25	0	0	0	0	0	1	0	1	2
26	0	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0	0
28	0	0	0	0	1	1	0	0	2
29	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0
31	0	0	1	0	1	0	0	1	3
32	0	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0	0
Mean	0.09	0.00	0.09	0.03	0.06	0.24	0.12	0.15	0.79
Standard Deviation	0.29	0.00	0.29	0.17	0.24	0.56	0.33	0.36	1.02

24. APPENDIX 12: INDIVIDUAL TOLERABILITY SELF-ASSESSMENT RESPONSES

Subject Number	BASELINE				WEEK 6			
	Stinging	Burning	Itching	Dryness - tightness	Stinging	Burning	Itching	Dryness - tightness
1	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0
4	0	0	0	0	0	0	0	0
5	0	0	0	0	0	0	0	0
6	0	0	0	0	0	0	0	0
7	0	0	0	0	0	0	0	0
8	0	0	0	0	0	0	0	0
9	0	0	0	0	0	0	0	0
10	0	0	0	0	0	0	0	0
11	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0
13	0	0	0	0	0	0	0	0
14	0	0	0	0	0	0	0	0
15	0	0	0	0	0	0	0	0
16	0	0	0	0	0	0	0	0
17	0	0	0	0	0	0	0	0
18	0	0	0	0	0	0	0	0
19	0	0	0	0	0	0	0	0
20	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0
22	0	0	0	0	0	0	0	0
23	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0
25	0	0	0	0	0	0	0	0
26	0	0	0	0	0	0	0	0
27	0	0	0	0	0	0	0	0
28	0	0	0	0	0	0	0	0
29	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0
31	0	0	0	0	0	0	0	0
32	0	0	0	0	0	0	0	0
33	0	0	0	0	0	0	0	0
Mean	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**
Standard Deviation	**0**	**0**	**0**	**0**	**0**	**0**	**0**	**0**

25. APPENDIX 13: INDIVIDUAL SELF-PERCEPTION RESPONSES

Baseline

Sub No	1. How long have you been experiencing light to mild acne?	2. How often do you change or wash your regular fabric face towel?	3. Have you used any medication, creams, or treatments specifically for your acne?	4. Are you comfortable with documenting your experience during the trial?
1	15 Years	Weekly	Face washes	Yes
2	30 Years	3 Days	Tea Tree	Yes
3	5 + Years	2 Days	Acnecide	Yes
4	10 Years	Daily	Clearasil	Yes
5	On and off for the last 20 years	Weekly	Neutrogena	Yes
6	10 Years	I wash it every two days/replace monthly	Clean and Clear	Yes
7	10 Years	2 - 4 Days	Clearasil	Yes
8	5 Years	Weekly	Various creams/washes	Yes
9	8 Years	3 Days	Clear skin capsules	Yes
10	2 Years	Monthly Change wash regular	Face theory	Yes
11	10 Years	2 Days	Acnecide	Yes
12	15 Years	Daily	Cetaphil	Yes
13	5 Years	1 - 2 Days	Dermalex	Yes
14	15 + Years	3 Days	Green Tea	Yes
15	10 Years	Daily	Cera Ve	Yes
16	10 - 12 Years	3 Days	Acne Relief	Yes
17	25 Years	Daily	Clearasil	Yes
18	Since I was a teenager over 30 Years	Daily	Clearasil	Yes
19	20 + Years	Weekly	Acnecide	Yes
20	5 Years	2 - 3 Days	Neutrogena	Yes
21	20 + Years	Weekly	LED Mask along with face wash	Yes
22	30 Years	4 Days	Acnecide	Yes
23	10 Years	Daily	Clearasil	Yes
24	10 Years	2 - 3 Days	The Body Shop	Yes
25	4 Years	Monthly	Neutrogena	Yes
26	20 Years	2 Days	Clearasil	Yes
27	10 + Years	2 Weeks	La Roche-Posay	Yes
28	20 + Years	5 Days	Tea Tree Dermalex	Yes
29	8 Years	Monthly	Clean and Clear	Yes
30	15 Years	Daily	Acnecide	Yes
31	20 + Years	2 Weeks	Sonic Facial Brush with cleanser	Yes
32	10 Years	Daily	Dove	Yes
33	6 Years	Daily	Tea Tree treatments	Yes

Week 3

Sub No	1. Have you noticed an improvement in the severity or frequency of breakouts?	2. Have you noticed any changes in your skin's dryness after using Clean Towels XL?	3. Have you noticed any changes in your skin's oiliness after using Clean Towels XL?	4. Have you noticed any changes in your skin's redness after using Clean Towels XL?	5. Have you noticed any changes in your skin's sensitivity after using Clean Towels XL?	6. Have you noticed any changes in your skin's overall health after using Clean Towels XL?
1	Not really	No	less oiliness	less redness	No Change	seems to be less oily
2	Yes	Yes not as dry	reduced the oiliness	improved	yes more these towels are gentle	skin has imporved overall
3	seem to have less breakouts	No	not as oily	skin isn't as red as usual	not as sensitive	not as many spots in breakouts
4	Definite improvement	skin isn't as dry	oils aren't as bad	a reduction in redness	a reduction in sensitivity	an overall improvement
5	Less frequent breakouts	Yes	less oiliness	skin not as red	skin not as sensitive	overall skin health has got better
6	Yes	less dryness	No Change	less redness	No Change	Improved
7	Improved	Same	towels have significantly reduced the oils	less redness	sensitivity improved	skin has more of a glow
8	breakouts reduced	less dryness	oiliness reduced	Not as red	No Change	less breakouts
9	not as may spots	dryness has reduced	reduced the oiliness	redness reduced	skin not as sensitive	spot reduction and improved sensitivty
10	Less frequent breakouts	skin not as flaky	not as oily	noticed after a week redness reduced	I noticed a reduction in sensitivty	overall health has improved
11	less frequent	No Change	No Change	redness reduced	skin not as sensitive	Overall Improvement
12	reduction in breakouts	Not as Dry	a reduction in oils	skin not as red	skin not as sensitive	Skin's looking and feeling healthier
13	there Is a noticable reduction in breakouts	No Change	oiliness reduced	No Change	No Change	less breakouts
14	Not as frequent	less dryness	oiliness reduced	doesn't seem to be as red	improvement in sensitivity	reduced the oil which in turn reduced my spots
15	a little improvement	There's a slight improvement	less oiliness	redness reduced	not as sensitive	so much better
16	Less frequent breakouts	less dryness	less oiliness	redness reduced	skin not as sensitive	health is better than a few weeks ago
17	No	No	less oiliness	No Change	No Change	just less oil
18	reduction in breakouts	No Change	oiliness reduced	Not as red	skin not as sensitive	less breakouts
19	Improved	less dryness	oiliness reduced	redness reduced	less sensitive	overall health has improved
20	Not as frequent	less dryness	same	Not as red	skin not as sensitive	skin feels healthier
21	spots have reduced since using	less dryness	oiliness reduced	redness reduced	less sensitive	looking healthy
22	Less frequent breakouts	No Change	less oily	redness reduced	No Change	yes looking healthier
23	breakouts Less Severe	less dryness	they reduced the oil	redness reduced	skin not as sensitive	Overall Improvement
24	No	No Change	not as oily	No Change	Less Sensitivity	looks healthier
25	less breakouts	less dryness	oiliness reduced	redness reduced	skin not as sensitive	good changes skin not as red
26	Severity has reduced	I've seen an improvement	oiliness reduced	redness reduced	No Change	Overall Improvement
27	I have noticed a reduction in breakouts	skin doesn't seem to be as dry	Skin isn't as oily	skin doesn't seem to be as red	an improvement	skin's looking better
28	Less Severe	less dryness	less oiliness	redness reduced	No Change	less breakouts
29	Less Frequent	less dryness	oiliness reduced	skin's redness has improved	less sensitive	skin is looking fresher
30	less breakouts	Not as Dry	oils reduced	No Change	skin not as sensitive	main change is the number of spots have halved
31	No Change	No Change	towels reduced the amount of oil my skin produced	No Change	skin not as sensitive	not much
32	Less frequent breakouts	less dryness	less oily	noticed a little improvement	skin not as sensitive	allround healthier skin
33	Less Severe	less dryness	skin's not as oily	redness reduced	No Change	the severity of my spots has reduced

Week 6

Sub No	1. Have you noticed an improvement in the severity or frequency of breakouts?	2. Have you noticed any changes in your skin's dryness after using Clean Towels XL?	3. Have you noticed any changes in your skin's oiliness after using Clean Towels XL?	4. Have you noticed any changes in your skin's overall health after using Clean Towels XL?	5. Have you noticed any changes in your skin's redness after using Clean Towels XL?	6. Have you noticed any changes in your skin's sensitivity after using Clean Towels XL?
1	Yes seen an improvement	No	still less oiliness	skin is healthier	less redness	No
2	Yes	skin dryness reduced	oiliness reduced	Overall Improvement	redness reduced	a lot less sensitivity
3	seem to have less breakouts	a little improvement	not as oily	less breakouts	still have a little redness but not as much as before	not as sensitive
4	Noticed an improvement	skin isn't as dry	saw a reduction	an overall improvement	a reduction in redness	a reduction in sensitivity
5	spots are less frequent	Yes	less oiliness	just healthier overall	skin not as red	skin not as sensitive
6	getting less than half what I had at the start	less dryness	No Change	improved skin health	less redness	skin not as sensitive
7	Improved	No Change	less oily skin	skin is lookng a lot cleaner	a definite reduction in redness	sensitivity improved
8	less breakouts	less dryness	reduction	skin health has improved	Not as red	No Change
9	less breakouts	dryness has reduced	reduced the oiliness	a lot less sensitive	redness reduced	skin not as sensitive
10	improved so much	Not as Dry	not as oily	overall health has improved	got better over the weeks	I noticed a reduction in sensitivty
11	Less frequent breakouts	noticed my skin doesn't feel as dry as ususal	No Change	skins overall health has improved	redness reduced	skin not as sensitive
12	breakouts were reduced	Not as Dry	saw an improvement after a couple of weeks regrading the oiliness	Skin's looking healthier	a lot less red	skin not as sensitive
13	the frequency of my breakouts has improved	No Change	oiliness reduced	a lot better	No Change	No Change
14	can see and feel the improvement	less dryness	oiliness reduced	reduction in spot meaning healthier skin	doesn't seem to be as red	improvement in sensitivity
15	a noticable improvement in severity	definte improved my dryness	less oiliness	a lot better	redness reduced	skins sensitivity had reduced
16	less spots	less dryness	a lot less oils	overall health has improved	skin isn't as red	skin not as sensitive
17	same amount of breakouts but less spots	skin does not feel as dry to touch	less oiliness	noticed a difference	No Change	No Change
18	breakouts are less frequent	No Change	pores have been unclogged less oil	not as frequent with breakouts	compared to the start its a lot less red	skin not as sensitive
19	noticed a reduction in breakouts	less dryness	oiliness reduced	overall health has improved	redness reduced	less sensitive
20	Not as frequent	towels have reduced dryness	I've noticed a slight improvement	overall healtheir	skins looking better	skin not as sensitive
21	my spots have reduced	less dryness	oiliness reduced	looking healthy	redness reduced	less sensitive
22	Less frequent breakouts	No Change	oiliness reduced	I've noticed a differnce over the weeks such an improvement	redness reduced	slight difference in sensitivity reduction
23	breakouts aren't as severe	less dryness	gently removed the oils	Overall Health Improvement	can see an improvement in how red my skin is	skin not as sensitive
24	No	No Change	was good at getting rid of excess oil	looks healthier	No Change	Less Sensitivity
25	less breakouts	less dryness	oiliness reduced	significant changes so much healthier	less redness	skin not as sensitive
26	Severity has reduced	I've seen an improvement	oiliness reduced	Overall Improvement	redness reduced	No Change
27	less spots	skin doesn't seem to be as dry	not as oily	skin is looking better	less redness	I can feel the differnce to the beginning of the trail
28	Less Severe	less dryness	less oiliness	clearer skin	redness reduced	No Change
29	frequency has gone down	less dryness	oiliness reduced	fresher looking	skin's redness has improved	less sensitive
30	less breakouts	Not as Dry	oils reduced	a mass reduction in spots and there frequency	No Change	skin not as sensitive
31	starting to see and feel the difference	No Change	less oils on my face	the more I use them Im seeing the progress	less redness	I've noticed a differnce it's improved
32	not as severe	less dryness	less oily	healthier looking overall	noticed a little improvement	skin not as sensitive
33	breakouts are less frequent	less dryness	skin's not as oily	skin is looking freshher	redness reduced	No Change

Sub No	7. Would you consider continuing to use Clean Towels XL, based on your experience?	8. Have you found Clean Towels XL to be an effective tool in managing the frequency and severity of your acne?	9. Would you recommend Clean Towels XL to a friend or family member?	10. After using Clean Towels XL, have you noticed improvements in your self-confidence or well-being as a result of changes in your skin condition?	11. While using Clean Towels XL, did you experience any unexpected benefits? Please describe.	12. Would you go back to using a regular fabric face towel after trying Clean Towels XL? Why or why not?
1	Yes	Yes	Yes	Yes	No	No Prefer these so much more
2	Yes	Yes	Yes	Yes	The experience was better than expected	these clothes are better
3	Yes	Yes	Yes	Yes	The reduction in oil	loved these towels
4	Yes	Yes	Yes	Yes	the overall improvement of my skin	No I would use these above my old ones
5	Yes	Yes	Yes	Yes	these felt nice	Think I would use both
6	Yes	Yes	Yes	Yes	they made my skin clearer	no I like the way these my make me feel about myself
7	Yes	Yes	Yes	Yes	No	no these towels are a better quality
8	Yes	Yes	Yes	Yes	great towels the were nice and gentle	not sure depends how expensive these would be I'm on a budget
9	Yes	Yes	Yes	Yes	good these towels	I prefer these ones but would use them alongside my usual ones
10	Yes	Yes	Yes	Yes	less spots	these are so much better for my skin so the asnwer is no I wouldn't go back
11	Yes	Yes	Yes	Yes	skin's feeling good	No better overall
12	Yes	Yes	Yes	No	the more I used them the clearer my skin got	like these better
13	Yes	Yes	Yes	Yes	I thought they'd be good but they worked a treat	No Prefer these ones
14	Yes	Yes	Yes	Yes	noticed an overall improvement	Mine were nothing on these clean towels
15	Yes	Yes	Yes	Yes	benefits of having healthier looking skin	just for how my skin's looking I'd stick withy these
16	Yes	Yes	Yes	Yes	not as many spots which is a plus	I like both to be fair but these towels just pip my usual
17	Yes	Yes	Yes	No	an improvement overall	these towels are much better than my previous ones
18	Yes	Yes	Yes	Yes	redness reduced	what's the saying don't go back well I certainly won't be
19	Yes	Yes	Yes	Yes	they felt nice to use	enjoyed the ones on this trial more
20	Yes	Yes	Yes	Yes	felt nice against my skin	no wouldn't go back to fabric ones
21	Yes	Yes	Yes	Yes	they were enjoyable to use and worked	these are much better than mine
22	Yes	Yes	Yes	Yes	they did a decent job on my skin	no this xl towel is a higher quality and has left my skin feeling fantastic
23	Yes	Yes	Yes	Yes	I enjoyed the experience	the towels we've been using over these weeks seem to better than mine
24	Yes	No	Yes	No	Not really	I would use them alongside mine
25	Yes	Yes	Yes	Yes	no	I wouldn't go back
26	Yes	Yes	Yes	No	good towels	enjoyed these ones more my skin looks more youthful
27	Yes	Yes	Yes	Yes	gave my skin a decent balance	yes prefer these ones
28	Yes	Yes	Yes	Yes	less spots	the tclean towels xl are much better
29	Yes	Yes	Yes	Yes	less breakouts	the xl towels are better quality
30	Yes	Yes	Yes	Yes	good for sensitive skin	I would only go back if I ran outta of these
31	Yes	Yes	Yes	No	no	I'd choose these ones
32	Yes	Yes	Yes	Yes	benefits of clearer skin	no chance I'd rather stick with these ones
33	Yes	Yes	Yes	Yes	less breakouts	I like these ones so much more